Structure Therapeutics Inc. (the “Company”) is a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The Company was incorporated in February 2019 in the Cayman Islands, with operating subsidiaries in the United States and China. In June 2022, the Company changed its name from ShouTi Inc. to Structure Therapeutics Inc.
Company profile
Ticker
GPCR
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ShouTi Inc.
SEC CIK
Corporate docs
Subsidiaries
Annapurna Bio Pty Limited • Annapurna Bio, Inc. • Basecamp Bio Hong Kong Limited • Basecamp Bio Inc. • Basecamp Bio USA Inc. • Gasherbrum Bio, Inc. • Lhotse Bio, Inc. • Shanghai Basecamp Biotechnology Co., Ltd. • Shanghai ShouTi Biotechnology Co., Ltd. • ShouTi Hong Kong Limited ...
IRS number
981480821
GPCR stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
27 Jun 24
424B4
Prospectus supplement with pricing info
6 Jun 24
EFFECT
Notice of effectiveness
6 Jun 24
S-1MEF
Registration of additional securities for an S-1
5 Jun 24
8-K
Other Events
3 Jun 24
S-1
IPO registration
3 Jun 24
8-K
Regulation FD Disclosure
3 Jun 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
9 May 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
Latest ownership filings
4
TED W LOVE
27 Jun 24
4
Joanne Waldstreicher
27 Jun 24
4
ERIC DOBMEIER
27 Jun 24
4
SHARON TETLOW
27 Jun 24
4
DANIEL G WELCH
27 Jun 24
4
Raymond C Stevens
14 Jun 24
3
Initial statement of insider ownership
13 Jun 24
4
Raymond C Stevens
12 Jun 24
144
Notice of proposed sale of securities
10 Jun 24
4
Xichen Lin
5 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 97.83 mm | 97.83 mm | 97.83 mm | 97.83 mm | 97.83 mm | 97.83 mm |
Cash burn (monthly) | 10.65 mm | 2.39 mm | 10.67 mm | 9.60 mm | 11.36 mm | 7.77 mm |
Cash used (since last report) | 41.20 mm | 9.24 mm | 41.27 mm | 37.10 mm | 43.93 mm | 30.05 mm |
Cash remaining | 56.64 mm | 88.60 mm | 56.56 mm | 60.73 mm | 53.90 mm | 67.78 mm |
Runway (months of cash) | 5.3 | 37.1 | 5.3 | 6.3 | 4.7 | 8.7 |
Institutional ownership, Q1 2024
41.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 25 |
Opened positions | 6 |
Closed positions | 63 |
Increased positions | 8 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 39.23 bn |
Total shares | 19.28 mm |
Total puts | 171.20 k |
Total calls | 280.20 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Wellington Management | 15.88 mm | $692.70 mm |
Biotechnology Value Fund L P | 2.44 mm | $82.51 mm |
Money Concepts Capital | 376.57 k | $16.14 bn |
TD Asset Management | 143.10 k | $6.13 bn |
Candriam Luxembourg S.C.A. | 135.00 k | $5.79 bn |
Susquehanna International | 81.79 k | $3.51 bn |
Allspring Global Investments | 47.27 k | $2.03 bn |
TrueMark Investments | 29.88 k | $1.28 bn |
AlphaCentric Advisors | 27.50 k | $1.18 bn |
Simplex Trading | 22.97 k | $984.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Jun 24 | Love Ted W | Share Option Ordinary Shares | Grant | Acquire A | No | No | 13.32 | 33,595 | 447.49 k | 33,595 |
25 Jun 24 | Joanne Waldstreicher | Share Option Ordinary Shares | Grant | Acquire A | No | No | 13.32 | 37,500 | 499.50 k | 37,500 |
25 Jun 24 | Tetlow Sharon | Share Option Ordinary Shares | Grant | Acquire A | No | No | 13.32 | 37,500 | 499.50 k | 37,500 |
25 Jun 24 | Dobmeier Eric | Share Option Ordinary Shares | Grant | Acquire A | No | No | 13.32 | 37,500 | 499.50 k | 37,500 |
25 Jun 24 | Welch Daniel G | Share Option Ordinary Shares | Grant | Acquire A | No | No | 13.32 | 37,500 | 499.50 k | 37,500 |
News
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
17 Jul 24
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
17 Jul 24
ASML Reports Q2 Results, Joins Spirit Airlines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
17 Jul 24
Peering Into Structure Therapeutics's Recent Short Interest
15 Jul 24
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
20 Jun 24
Press releases
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares
7 Jun 24
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
5 Jun 24
Qiming's Nisa Leung Made the 2024 Forbes Midas List
4 Jun 24
MAIA Biotechnology (MAIA) to Showcase Groundbreaking Telomere-Targeting Cancer Treatments at BIO International Convention 2024
4 Jun 24
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
3 Jun 24